Defective Genome Instability Suppressing Genes May Cause Some Types of Cancer
|
By LabMedica International staff writers Posted on 28 Apr 2016 |

Image: Drop-inoculation of Saccharomyces cerevisiae mutants on an agar plate. The assay compares the viability of different yeast mutants (Photo courtesy of Wikimedia Commons).
Cancer researchers reported in a recent study that defects in the expression of genes that suppress gross chromosomal rearrangements (GCRs) were linked to more than 93% of the ovarian and 66% of the colorectal cancer cases they had examined.
Investigators at the University of California, San Diego (USA) worked with the yeast Saccharomyces cerevisiae to identify genome instability suppressing (GIS) genes that acted to prevent chromosomal rearrangements. They reported in the April 13, 2016, online edition of the journal Nature Communications that by using this platform they had been able to identify182 GIS genes that suppressed GCR formation. Another 438 cooperatively acting GIS genes (cGIS) were identified that were not GIS genes, but suppressed the increased genome instability caused by individual query mutations.
Analysis of data derived from The Cancer Genome Atlas (TCGA) allowed the investigators to predict which human genes were associated with GIS pathways. This analysis revealed that a minimum of 93% of ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS gene. These defects included loss-of-function mutations, copy-number changes associated with reduced expression, and silencing. In contrast, acute myeloid leukemia cases did not appear to have defects affecting the predicted GIS genes.
"Mutated GIS genes have long been suspected of playing a role in the development of many types of cancers, but identifying them has been difficult due in large part to a lack of comprehensive GCR tests, or assays, in mammalian systems," said first author Dr. Christopher Putnam, adjunct assistant professor of medicine at the University of California, San Diego School of Medicine. "Before our experiment, only a few dozen cGIS genes were known. Now we know of hundreds. Understanding this process allows us to think more about how carcinogenesis proceeds and it might give us insights into defects that could be therapeutically actionable in the future."
Related Links:
University of California, San Diego
Investigators at the University of California, San Diego (USA) worked with the yeast Saccharomyces cerevisiae to identify genome instability suppressing (GIS) genes that acted to prevent chromosomal rearrangements. They reported in the April 13, 2016, online edition of the journal Nature Communications that by using this platform they had been able to identify182 GIS genes that suppressed GCR formation. Another 438 cooperatively acting GIS genes (cGIS) were identified that were not GIS genes, but suppressed the increased genome instability caused by individual query mutations.
Analysis of data derived from The Cancer Genome Atlas (TCGA) allowed the investigators to predict which human genes were associated with GIS pathways. This analysis revealed that a minimum of 93% of ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS gene. These defects included loss-of-function mutations, copy-number changes associated with reduced expression, and silencing. In contrast, acute myeloid leukemia cases did not appear to have defects affecting the predicted GIS genes.
"Mutated GIS genes have long been suspected of playing a role in the development of many types of cancers, but identifying them has been difficult due in large part to a lack of comprehensive GCR tests, or assays, in mammalian systems," said first author Dr. Christopher Putnam, adjunct assistant professor of medicine at the University of California, San Diego School of Medicine. "Before our experiment, only a few dozen cGIS genes were known. Now we know of hundreds. Understanding this process allows us to think more about how carcinogenesis proceeds and it might give us insights into defects that could be therapeutically actionable in the future."
Related Links:
University of California, San Diego
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Blood Test Shows Extent of Brain Injury After Stroke
Ischemic stroke is a medical emergency, yet clinicians can only observe brain injury through snapshots provided by CT or MRI scans. These images offer limited insight into how damage evolves over hours... Read more
Novel Liquid Biopsy Technology to Advance Cancer Diagnostics
Liquid biopsies are increasingly replacing tissue biopsies in cancer care, offering a faster, minimally invasive way to assess tumor genetics from blood samples. However, current liquid biopsy methods... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more







